ANGPT1 and neoplasm: The favorable safety profile of Ang-2 selective antibodies in combination with their anti-tumor, anti-metastatic and anti-angiogenic potential demonstrate a substantial benefit of Ang-2 targeting in oncology whereas the benefits of Ang-1 targeting remain debatable.